Trimel's product candidate Tefina™ is an intranasal, low-dose gel formulation of testosterone. Tefina™ is being developed to offer women experiencing Female Orgasmic Disorder ("FOD") a "use as required" treatment option. FOD is defined as the persistent or recurrent delay in, or absence of, orgasm following a normal sexual excitement phase that causes marked personal distress or interpersonal difficulties. The etiology of FOD is often characterized by whether the dysfunction has been lifelong (primary) or acquired (secondary).
If successfully developed and approved, the "use as required" treatment regimen for Tefina™ is intended to present an attractive safety profile with virtually no androgen-related side effects such as acne, facial and body hair growth or deepening of the voice. Moreover, there is no expected risk of skin-to-skin transfer of testosterone to third parties with the nasal dispenser.